|Seasoned Healthcare Executive Albert P. Parker Appointed Chief Operating Officer of OncoCyte|
August 09, 2018
|ALAMEDA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the appointment of Albert P. Parker, a seasoned industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Operating Officer.
“I welcome Al to OncoCyte and I, along with the other senior executives, look forward to his many contributions,” commented Wil... |
|Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress|
August 09, 2018
|Company Progressing Neurology and Immunotherapy Clinical Programs
Anticipates Achievement of Significant Execution Milestones in the Second Half of 2018 and Full Year 2019 to Advance the Development of its Platform Technologies
Conference Call and Webcast Today, August 9, at 5:00 p.m. ET
FREMONT, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological condit... |
|BioTime Reports Second Quarter Results and Recent Corporate Accomplishments|
August 02, 2018
|BioTime to receive $43 million from Juvenescence
BioTime shareholders to receive one share of AgeX common stock for
every 10 shares of BioTime common stock held
BioTime clinical programs including OpRegen® for dry-AMD
and Renevia® for volume enhancement are on track
Conference call and webcast today at 1:30pm PT/4:30pm ET
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 2, 2018--
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|